Evaluation of the Safety, Tolerability, and Efficacy of the Omega System for the Treatment of LUTS Due to BPH
Study Details
Study Description
Brief Summary
This is a prospective, two-stage, multi-center, pilot clinical study to evaluate the safety/tolerability/efficacy of the Omega System device. The Omega arc-shaped implant is inserted by the Omega delivery system into the prostate tissue of subjects to relieve lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The study will first evaluate the Omega system on patients undergoing prostatectomy, which is not indicated for the device.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Omega procedure
|
Device: Omega device
The ProArc Medical Omega system is a prostatic reshaping device. The Omega System is comprised of two main components: Omega Delivery Device and Omega g Implant.
The delivery system uses a diathermy electrode to perform a circular and superficial incision through the urethral wall into the prostate tissue, into which the arc-shaped permanent implant is placed. The implant is made up of commonly used surgical implantable nitinol material, coated with Parylene coating. The implant expands the obstructed area, reducing the fluid obstruction through the prostatic urethra.
|
Outcome Measures
Primary Outcome Measures
- Primary Safety (Stage 1 and Stage 2) - Incidence and severity of procedural and device related adverse events. [12 Months]
Incidence and severity of procedural and device related adverse events.
- Primary Safety (Stage 2) - Incidence of post-operative catheterization after 7 days, up to 14 days. [2 weeks]
Incidence of post-operative catheterization after 7 days, up to 14 days.
- Efficacy (Stage 2) - Change in urinary related symptom [3 Months]
Improvement in urinary related symptoms as evidenced by at least 25% decrease in International Prostate Symptom Score (A score of 0-7 indicates mild symptoms, 8-19 indicates moderate symptoms and 20-35 indicates severe symptoms)
Secondary Outcome Measures
- Functionality (Stage 1) - Location and orientation of Omega implant in the prostate before prostatectomy is as planned: Yes/No [Procedure day]
Evaluating whether the outcome of the Omega implant's location and orientation turned out as the surgeon planned prior to the Omega procedure.
- Functionality (Stage 1) - Location and depth Omega incision in the excised prostate is as planned: Yes/No. [Procedure day]
Evaluating whether the Omega incision location and depth outcome turned out as the surgeon planned prior to the Omega procedure.
- Usability (Stage 1 and Stage 2) - Evaluate the usability of the device and entire process [Procedure day]
Evaluate the usability of the device and the entire process using the usability questionnaire (The highest score of 60 indicates that the device is extremely user-friendly, while the lowest score of 12 indicates that the device is very difficult to use)
- Efficacy (Stage 2) - Improvement in urinary related symptoms [1 Months, 6 Months and 12 months]
Evaluate the improvement in urinary-related symptoms as evidenced by a decrease of at least 25% in the IPSS score. (A score of 0-7 indicates mild symptoms, 8-19 indicates moderate symptoms and 20-35 indicates severe symptoms)
- Efficacy (Stage 2) - Improvement of peak urinary flow rate as evidenced by an increase of at least 25% in uroflowmetry Qmax [1 Months, 3 Months, 6 Months and 12 months]
- Exploratory - Change in PSA [1 Months, 6 Months and 12 Months]
- Exploratory - Change in sexual function assessments from screening to 3, 6 and 12 months using the International Index of Erectile Function (IIEF) and Male Sexual Health Questionnaire for Ejaculatory Function (MSHQ-EjD). [3 Months, 6 Months and 12 months]
The IIEF-5 score ranges from 5 to 25 and is used to classify erectile dysfunction (ED) into five categories based on the scores: no ED (22-25), mild (17-21), mild to moderate (12-16), moderate (8-11), and severe (5-7). An MSHQ-EjD score of 20 indicates the absence of ejaculatory dysfunction, while a score of 0 indicates a high level of ejaculatory dysfunction.
- Exploratory - Change in VAS pain score [1-2 weeks and 1 month]
A VAS pain score of (0-1 mm) indicates no pain,(2-4 mm) - mild pain, (4-7 mm) - moderate pain, and (7-10 mm) - severe pain.
- Exploratory - Change in post-void residual (PVR) test [1 Months, 3 Months, 6 Months and 12 months]
- Exploratory - Incidence of inflammation, assessed by cystoscope [6 months]
- Exploratory - Omega coverage assessed by cystoscope [6 months]
Eligibility Criteria
Criteria
Stage 1
Inclusion Criteria:
-
Male ≥50 years of age and ≤ 80 years old.
-
Will undergo planned prostatectomy.
-
Participant understands and is willing to the informed consent form.
-
Prostate Volume between 30cc and 80cc.
-
Prostate length ≥ 3cm
Exclusion Criteria:
-
Unable to comply with the clinical protocol.
-
Vulnerable population such as inmates or developmentally delayed individuals.
-
Any medical condition or treatment, which in the opinion of the investigator may interfere with the procedure, such as:
-
Patient with coagulopathy due to medications or congenital condition - inability to stop taking anticoagulants and/or antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure (low dose aspirin therapy is not prohibited).
-
Use of alpha-blockers within 2 weeks of pre-treatment (baseline) evaluation.
-
Use of 5-α-reductase inhibitors within 6 months of pre-treatment (baseline) evaluation.
-
American Society of Anesthesiologists score (ASA) ≥ 3.
-
Previous prostate surgery such as: TURP, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate.
-
Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate.
-
Other urethral conditions that may prevent insertion of Delivery Device into prostatic urethra.
-
Previous rectal surgery, other than hemorrhoidectomy
-
Current gross hematuria.
-
Known allergy to nickel or titanium or stainless steel.
Stage 2
Inclusion Criteria:
-
Male ≥50 years of age and ≤ 80 years old.
-
Suspected symptomatic benign prostatic hyperplasia (BPH).
-
International Prostate Symptom Score (IPSS) >13.
-
Peak flow rate ≤ 12 ml/sec (with voided volume ≥ 125ml).
-
Participant understands and is willing to the informed consent form.
-
Prostate Volume between 30cc and 80cc.
-
Prostate length ≥ 3cm and ≤ 5cm
Exclusion Criteria:
-
Diagnosed or suspected prostate cancer. If suspected, prostate cancer must be ruled out.
-
Concomitant participation in another interventional study.
-
Unable to comply with the clinical protocol including all the follow-up requirements.
-
Vulnerable population such as inmates or developmentally delayed individuals.
-
Significant comorbidities which would affect study participation.
-
Any medical condition or treatment, which in the opinion of the investigator may interfere with the procedure ,such as:
-
Use of concomitant medications (e.g., anticholinergics, antispasmodics, or antidepressants) affecting bladder function.
-
Patient with coagulopathy due to medications or congenital condition - inability to stop taking anticoagulants and/or antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure; low dose aspirin therapy not prohibited.
-
Alpha-blockers within 2 weeks of pre-treatment (baseline) evaluation.
-
Taking 5-α-reductase inhibitors within 6 months of pre-treatment (baseline) evaluation.
-
Patient is taking steroids. [Note: Patients approved for the trial who are using the above medications will continue using them after the trial, except for Alpha blockers and 5-α-reductase.]
-
Previous prostate surgery such as: TURP, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate.
-
Compromised renal function due to obstructive uropathy.
-
Active Urinary Tract Infection (UTI).
-
Intravesical lobe (if approved by prior cystoscopy).
-
Obstructive median lobe.
-
American Society of Anesthesiologists score (ASA) ≥ 3.
-
Known neurogenic bladder or neurological disorders that might affect bladder or function.
-
Recent myocardial infarction (less than three months).
-
Concomitant bladder stones.
-
Current gross hematuria.
-
Active or history of epididymitis within the past 3 months.
-
Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate.
-
Confirmed or suspected malignancy of bladder.
-
History or presence of strictures in the anterior urethra or bladder neck contracture or detrusor muscle spasms.
-
Other urethral conditions that may prevent insertion of Delivery Device into prostatic urethra.
-
Bacterial prostatitis within the last 12 months.
-
Diagnosed with Chronic Pelvic Pain Syndrome (CPPS).
-
Previous rectal surgery, other than hemorrhoidectomy.
-
Current uncontrolled diabetes (i.e., hemoglobin A1c ≥ 9%).
-
Known allergy to nickel or titanium or stainless steel.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | JSC L.Managadze National Center of Urology | Tbilisi | Georgia | ||
| 2 | Todua Clinic | Tbilisi | Georgia |
Sponsors and Collaborators
- ProArc Medical
Investigators
- Study Director: Frank Mastandrea, Dr, Board Member and Medical Director
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PA-CP-22